Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: A 3-month follow-up

Journal of Psychopharmacology

Volumn 23, Issue 8, 2009, Pages 915-922

  Medved, V ^a   Kuzman, M R ^a   Jovanovic, N ^a   Grubisin, J ^a   Kuzman, T ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Diabetes; Female; Metabolic syndrome; Olanazapine; Risperidone; Schizophrenia

Indexed keywords

CHOLESTEROL; CLONAZEPAM; DIAZEPAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DELUSIONAL DISORDER; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DROWSINESS; EDEMA; EXTRAPYRAMIDAL SYNDROME; FAMILY HISTORY; FEMALE; FOLLOW UP; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HIP; HOSPITAL ADMISSION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; POPULATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; SCHIZOPHRENIA;

EID: 70449371255     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108093927     Document Type: Article

References (30)

1. Aichhorn, W., Gasser, M., Weiss, EM, Adlassnig, C., Marksteiner, J. (2005) Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr Neuropharmacol 3: 73-85.
2. Atmaca, M., Kuloglu, M., Tezcan, E., Ustundag, B. (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64: 598-604. (Pubitemid 36618291)
3. Bierman EL (1997) Atherosclerosis and other forms of arteriosclerosis. In Ivancevic Z, Rumbolt Z, Bergovec M, Silobrcic V, Bruketa D: Harrisons Principles Of Internal Medicine 9th Edition, 1st Croatian edition, eds. XIII, Split, Placebo, pp. 965-973. [ http://www.idf.org/webdata/docs/IDF-Meta-def- final.pdf ].
4. Bozina, N., Medved, V., Kuzman, MR, Sain, I., Sertic, J. (2007) Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 21: 728-734.
5. Brunzell, JD, Ayyobi, AF (2003) Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 8 (115 Suppl. 8A). 24S - 28S.
6. Hanley, AJ, Wagenknecht, LE, DAgostino, RB, Zinman, B., Haffner, SM (2003) Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52: 2740-2747.
7. Lee, IM, Paffenbarger, RS (1992) Changes in body weight and longevity. JAMA 268: 2045-2049.
8. Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
9. Lindenmayer, JP, Nathan, AM, Smith, RC (2001) Hyperglycemia associated with use of atypical antipsychotics. J Clin Psychiatry 62 (Suppl. 23). 30-38.
10. Lindenmayer, JP, Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, JP, et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290-296.
11. McEvoy, JP, Meyer, JM, Goff, DC, Nasrallah, HA, Davis, SM, Sullivan, L., et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80: 19-32.
12. Melkersson, K., Hulting, AL, Hall, K. (1999) Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuro Endocrinol Lett 20: 199-204.
13. Mokdad, AH, Serdula, MK, Dietz, WH, Bowman, BA, Marks, JS, Koplan, JP (1999) The spread of obesity epidemic in the Unites States, 1991-1998. JAMA 282: 1519-1522.
14. Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., Scapicchio, PL (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37: 68-73.
15. Mukherjee, S., Schnur, DB, Reddy, R. (1989) Family history of type 2 diabetes in schizophrenic patients. (letter) Lancet 1: 495.
16. Nasrallah, HA, Newcomer, JW (2004) Atypical antipsychotics and metabolic dysregulation evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 5 (Suppl. 1). pp. S7 - S14.
17. Newcomer, JW (2004) Metabolic risk during antipsychotic treatment. Clin Ther 26: 1936-1946.
18. Olfson, M., Marcus, SC, Corley-Lisle, P., Tuomari, AV, Hines, P., LItalien, GJ (2006) Hyperlipidemia following treatment with antipsychotic medications. Am J Psy 163: 1821-1826.
19. Pavlic-Renar, T., Poljicanin, Z., Metelko, Z. (2005) Metabolic syndrome and its significance for public health. Oral presentation and abstract book, p. 18 at Croatian Academy of medical sciences. Metabolic syndrome and its significance for public health. Zagreb: Public Health Symposium: Distribution of population cardiovascular risks in Croatia, December 2.
20. Perez-Iglesias, R., Crespo-Facorro, B., Amado, JA, Garcia-Unzueta, MT, Ramirez-Bonilla, ML, Gonzalez-Blanch, C., et al. (2007) A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 68: 1733-1740.
21. Ryan, MCM, Collins, P., Thakore, JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
22. Sarafidis, PA, Nilsson, PM (2006) The metabolic syndrome: a glance at its history. J Hypertens 24: 621-626.
23. Smith, RC, Lindenmayer, JP, Bark, N., Warner-Cohen, J., Vaidhyanathaswamy, S., Khandat, A. (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenia patients. Int J Neuropsychopharmacol 8: 183-194.
24. Sussman, N. (2001) Review of atypical antipsychotics and weight gain. J Clin Psychiatry 62 (Suppl. 23). 5-12.
25. Thonnard-Neumann, E. (1945) Phenothiazines and diaetes in hospitalized women. Am J Psychiatry 102: 108-110.
26. Thonnard-Neumann, E. (1968) Phenothiazines and diaetes in hospitalized women. Am J Psychiatry 124: 978-982.
27. Volavka, J., Czobor, P., Cooper, TB, Sheitman, B., Lindenmayer, JP, Citrome, L., et al. (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65: 57-61.
28. Weiden, PJ, Mackell, JA, McDonnell, DD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66: 51-57.
29. Wu, RR, Zhao, JP, Liu, ZN, Zhai, JG, Guo, XF, Guo, WB, et al. (2006) Effects of typical and atypical antipsychotics on glucose- insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 186: 572-578.
30. Wu, RR, Zhao, JP, Zhai, JG, Guo, XF, Guo, WB (2007) Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 27: 374-379.